.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Alzheimer’s disease presents a significant challenge for modern medicine, creating an urgent need for neuroregenerative treatments. Recent research indicates that NeuroD1 gene therapy effectively repairs functional brain damage in non-human primate models. This innovative approach targets hippocampal degeneration, which typically leads to severe memory loss.
Scientists utilized an adeno-associated virus (AAV) vector to deliver the NeuroD1 gene into the hippocampus. Consequently, the therapy prevented neuronal damage and significantly reduced neuroinflammation. Moreover, researchers observed a restoration of the blood-brain barrier and vascular integrity. These improvements coincided with enhanced spatial working memory and stabilized hippocampal glucose metabolism.
The study employed advanced imaging, including MRI and FDG PET scans, to monitor brain changes. Results showed that the treatment inhibited hippocampal atrophy. Furthermore, transcriptome analysis confirmed the upregulation of neuronal function and synaptic transmission pathways. Because the primate model closely reflects human pathology, these findings offer substantial hope for future clinical applications.
It acts as a master transcription factor that facilitates the conversion of glial cells into functional neurons, thereby repairing damaged brain circuits.
The therapy restores CSF AD biomarker levels to more normal ranges, suggesting a systemic improvement in brain health and pathology.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Jiang Z et al. A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease-Like Non-Human Primate Model. Adv Sci (Weinh). 2026 Mar 10. doi: 10.1002/advs.202520239. PMID: 41806359.
Ge L-J, et al. In vivo Neuroregeneration to Treat Ischemic Stroke Through NeuroD1 AAV-Based Gene Therapy in Adult Non-human Primates. Front Cell Dev Biol. 2020;8:590008.
Chen YC, et al. A NeuroD1 AAV-Based Gene Therapy for Functional Brain Repair after Ischemic Injury through In Vivo Astrocyte-to-Neuron Conversion. Mol Ther. 2020;28(1):217-234.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Research demonstrates that NeuroD1 AAV-based gene therapy repairs brain function, inhibits atrophy, and improves memory in Alzheimer's primate models....
6 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
